**PROGRAM AT A GLANCE**

**Day 1**

**January 27 / 28**

- **18:00 - 20:00**: Joint IASLC-CAAC-CSCO Session*

- **20:15 - 21:15**: I509: Satellite CME Symposium by Clinical Care Options**

- **21:30 - 22:30**: I502: Industry Symposium*

- **22:45 - 23:45**: I503: Industry Symposium*

**Day 2**

**January 28 / January 29**

- **00:00 - 01:00**: I504: Industry Symposium*

- **01:05 - 02:15**: I505: Industry Symposium*

- **02:30 - 03:30**: I506: Industry Symposium*

- **03:45 - 04:45**: I507: Industry Symposium*

- **05:00 - 07:00**: New York

- **07:00 - 08:00**: I508: Industry Symposium*

- **08:00 - 09:00**: I509: Industry Symposium*

- **09:00 - 10:00**: I510: Industry Symposium*

- **10:15 - 11:00**: I501: Choosing Systemic Therapy After Chemotherapy and Immunotherapy in NSCLC

- **11:00 - 12:00**: I502: Promoting Antibody Drug Conjugate and Cytotoxic Therapy in NSCLC

- **12:00 - 13:15**: I503: Industry Symposium*

- **13:30 - 14:30**: I504: Value in Lung Cancer from Screening to Treatment

- **14:30 - 15:30**: I505: Technological Advances in Diagnostics, Imaging and Therapeutics for Lung Cancer

- **15:30 - 16:30**: I506: Perioperative Therapy for Early Stage NSCLC

- **16:30 - 17:30**: I507: The New WHO Classification of Lung Tumors

- **17:30 - 18:30**: I508: The Solitary Pulmonary Nodule

- **18:30 - 19:30**: I509: New and Revisited Factors in Early Stage Lung Cancer

- **19:30 - 20:30**: I510: Pleural Effusion in a Cancer Patient

- **20:30 - 21:30**: I511: Updates on EGFR Targeted Perioperative Therapy and Precision Adjunct Chemotherapy

- **21:30 - 22:30**: I512: The Future of Immunotherapy in Unresectable NSCLC

- **22:30 - 23:30**: I513: The Future of Immunotherapy in Early Stage NSCLC

- **23:30 - 00:00**: I514: Presidential Symposium

**Day 3**

**January 29 / January 30**

- **00:00 - 01:00**: I701: Industry Symposium*

- **01:05 - 02:15**: I705: Industry Symposium*

- **02:30 - 03:30**: I706: Industry Symposium*

- **03:45 - 04:45**: I707: Industry Symposium*

- **05:00 - 07:00**: New York

- **07:00 - 08:00**: I708: Industry Symposium*

- **08:00 - 09:00**: I709: Industry Symposium*

- **09:00 - 10:00**: I710: Industry Symposium*

- **10:15 - 11:00**: I515: Novel Systemic Treatment in NSCLC

- **11:00 - 12:00**: I516: New Data from Rare EGFR Alterations

- **12:00 - 13:15**: I517: Strategies to Increase Cure Rates in Stage III NSCLC: OptimizingCheckpoint Inhibitors and Beyond

- **13:30 - 14:30**: I518: Novel Immunotherapy Strategies in NSCLC

- **14:30 - 15:30**: MA05: Lung Cancer Screening

- **15:30 - 16:30**: MA06: Improving Care for People with Lung Cancer: Decision Making, Survivorship, and New Challenges During COVID-19

- **16:30 - 17:30**: MA07: Innovative Strategies to Increase Cure Rates in Stage II NSCLC: Optimizing Checkpoint Inhibitors and Beyond

- **17:30 - 18:30**: MA08: Getting All NSCLC Genotyped: How Can We Get to 100%?

- **18:30 - 19:30**: MA09: Molecular Developments and Novel Treatments in Mesothelioma and Thymoma

- **19:30 - 20:30**: MA10: The Future of Immunotherapy in Unresectable NSCLC

- **20:30 - 21:30**: MA11: Improving Care for People with Lung Cancer: Decision Making, Survivorship, and New Challenges During COVID-19

- **21:30 - 22:30**: MA12: The Future of Immunotherapy in Unresectable NSCLC

- **22:30 - 00:00**: MA13: The Future of Immunotherapy in Early Stage NSCLC

**Day 4**

**January 30 / January 31**

- **00:00 - 01:00**: I519: Industry Symposium*

- **01:05 - 02:15**: I520: Industry Symposium*

- **02:30 - 03:30**: I521: Industry Symposium*

- **03:45 - 04:45**: I522: Industry Symposium*

- **05:00 - 07:00**: New York

- **07:00 - 08:00**: I523: Industry Symposium*

- **08:00 - 09:00**: I524: Industry Symposium*

- **09:00 - 10:00**: I525: Industry Symposium*

- **10:15 - 11:00**: I711: Industry Symposium*

- **11:00 - 12:00**: I712: Industry Symposium*

- **12:00 - 13:15**: I713: Satellite CME Symposium by ACE Oncology**

- **13:30 - 14:30**: I714: Industry Symposium*

- **14:30 - 15:30**: I715: Industry Symposium*

- **15:30 - 16:30**: I716: Joint Global Lung Cancer Coalition/IASLC Session: Hot Topics for Advocates

- **16:30 - 17:30**: I717: The New WHO Classification of Lung Tumors

- **17:30 - 18:30**: I718: The Solitary Pulmonary Nodule

- **18:30 - 19:30**: I719: Updates on EGFR Targeted Perioperative Therapy and Precision Adjunct Chemotherapy

- **19:30 - 20:30**: I720: The Future of Immunotherapy in Unresectable NSCLC

- **20:30 - 21:30**: I721: The Future of Immunotherapy in Early Stage NSCLC

- **21:30 - 22:30**: I722: The Future of Immunotherapy in Early Stage NSCLC

- **22:30 - 00:00**: I723: The Future of Immunotherapy in Early Stage NSCLC

- **00:00 - 01:00**: I724: Presidential Symposium

- **01:00 - 02:00**: I725: Presidential Symposium

- **02:00 - 03:00**: I726: Presidential Symposium
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>00:00 - 01:00</td>
<td>IS04: Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices</td>
</tr>
<tr>
<td>01:15 - 02:15</td>
<td>IS05: Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer</td>
</tr>
<tr>
<td>02:30 - 03:30</td>
<td>IS06: Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC</td>
</tr>
<tr>
<td>03:45 - 04:45</td>
<td>IS07: Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer</td>
</tr>
<tr>
<td>05:00 - 07:00</td>
<td>IS08: Industry Symposium Sponsored by AstraZeneca: Advances in Antibody-Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer</td>
</tr>
<tr>
<td>07:30 - 09:30</td>
<td>IS09: Industry Symposium Sponsored by Pfizer: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs</td>
</tr>
<tr>
<td>09:30 - 10:30</td>
<td>IS10: Industry Symposium Sponsored by Boehringer Ingelheim: Maximizing Immuno-Biology of Immunotherapy in Lung Cancer</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>IS11: Industry Symposium Sponsored by Janssen: Advances in Antibody-Drug Conjugates (ADC) as Therapeutic Options for Oligometastatic NSCLC</td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td>IS12: Industry Symposium Sponsored by Boehringer Ingelheim: Exploring the Future of Innovation in Lung Cancer Therapies</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>IS13: Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective</td>
</tr>
<tr>
<td>22:45 - 23:45</td>
<td>IS15: Industry Symposium Sponsored by Boehringer Ingelheim: Expert Insights on Recent Advances in Lung Cancer Immunology</td>
</tr>
<tr>
<td>00:00 - 01:00</td>
<td>IS16: Industry Symposium Sponsored by Boehringer Ingelheim: Next Generation of NSCLC Immunotherapy: Beyond Checkpoint Inhibitors</td>
</tr>
<tr>
<td>01:15 - 02:15</td>
<td>IS17: Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective</td>
</tr>
<tr>
<td>02:30 - 03:30</td>
<td>IS18: Industry Symposium Sponsored by Janssen: Maximizing Immuno-Biology of Immunotherapy in Lung Cancer</td>
</tr>
<tr>
<td>03:45 - 04:45</td>
<td>IS19: Industry Symposium Sponsored by Boehringer Ingelheim: Exploring the Future of Innovation in Lung Cancer Therapies</td>
</tr>
<tr>
<td>05:00 - 07:00</td>
<td>IS20: Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective</td>
</tr>
<tr>
<td>07:30 - 09:30</td>
<td>IS21: Industry Symposium Sponsored by Janssen: Advances in Antibody-Drug Conjugates (ADC) as Therapeutic Options for Oligometastatic NSCLC</td>
</tr>
<tr>
<td>09:30 - 10:30</td>
<td>IS22: Industry Symposium Sponsored by Boehringer Ingelheim: Maximizing Immuno-Biology of Immunotherapy in Lung Cancer</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>IS23: Industry Symposium Sponsored by Janssen: Advances in Antibody-Drug Conjugates (ADC) as Therapeutic Options for Oligometastatic NSCLC</td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td>IS25: Industry Symposium Sponsored by Janssen: Advances in Antibody-Drug Conjugates (ADC) as Therapeutic Options for Oligometastatic NSCLC</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>IS26: Industry Symposium Sponsored by Boehringer Ingelheim: Exploring the Future of Innovation in Lung Cancer Therapies</td>
</tr>
</tbody>
</table>

These programs were approved by the IASLC 2020 World Conference on Lung Cancer Program Committee as independent activities held in conjunction with the IASLC 2020 World Conference on Lung Cancer. These programs are not sponsored or endorsed by IASLC and are not part of the official IASLC accredited program.